Microbot Medical Inc.
MBOTHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeMicrobot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. At a $100.7M market cap, Microbot Medical Inc. ranks as a micro-cap company within healthcare. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations.
Market Cap
$100.7M
Beta
1.03
P/E (TTM)
—
P/E (Fwd)
-4.37
EPS (TTM)
$-0.25
EPS (Fwd)
$-0.34
ROE
-32.9%
ROA
-21.7%
Cash
$67.4M
Total Debt
$876,000
Free CF
-$14.2M
52W Change
-59.7%
Annual Financials
Cash vs Debt
Where MBOT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MBOT finished 27.72% below its 150-day moving average ($2.02) and 28.43% below its 200-day moving average ($2.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MBOT overbought or oversold?
At the September 3, 2026 close, MBOT's RSI(14) was 28.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $67.4M in cash comfortably exceeding the $876K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$14.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -32.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, MBOT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Microbot Medical Inc.'s trajectory.